See more : YPB Group Limited (YPB.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Aura Biosciences, Inc. (AURA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aura Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Chuang’s Consortium International Limited (0367.HK) Income Statement Analysis – Financial Results
- Odyssey Group International, Inc. (ODYY) Income Statement Analysis – Financial Results
- Union Corporation (000910.KS) Income Statement Analysis – Financial Results
- Evo Acquisition Corp. (EVOJW) Income Statement Analysis – Financial Results
- ENEA S.A. (ENEAY) Income Statement Analysis – Financial Results
Aura Biosciences, Inc. (AURA)
About Aura Biosciences, Inc.
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.30M | 1.18M | 835.00K | 831.00K | 509.00K |
| Gross Profit | -1.30M | -1.18M | -835.00K | -831.00K | -509.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 65.23M | 42.24M | 25.16M | 18.04M | 19.62M |
| General & Administrative | 19.76M | 18.06M | 10.09M | 4.16M | 4.52M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.76M | 18.06M | 10.09M | 4.16M | 4.52M |
| Other Expenses | 0.00 | -5.00K | -11.00K | 3.00K | -44.00K |
| Operating Expenses | 84.99M | 60.30M | 35.25M | 22.21M | 24.14M |
| Cost & Expenses | 84.99M | 60.30M | 35.25M | 22.21M | 24.14M |
| Interest Income | 0.00 | 1.86M | 13.00K | 3.00 | 5.00 |
| Interest Expense | 0.00 | 0.00 | 13.00K | 3.00K | 5.00K |
| Depreciation & Amortization | 1.30M | 1.18M | 835.00K | 831.00K | 509.00K |
| EBITDA | -83.70M | -59.12M | -34.42M | -21.38M | -23.63M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -84.99M | -60.30M | -35.25M | -22.21M | -24.14M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.72M | 1.53M | -1.00K | 0.00 | -60.00K |
| Income Before Tax | -76.27M | -58.76M | -35.25M | -22.21M | -24.20M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 137.00K | -1.53M | -830.00K | 3.00K | 5.00K |
| Net Income | -76.41M | -57.23M | -34.42M | -22.21M | -24.21M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.93 | -1.91 | -1.18 | -0.76 | -0.83 |
| EPS Diluted | -1.93 | -1.91 | -1.18 | -0.76 | -0.83 |
| Weighted Avg Shares Out | 39.62M | 29.94M | 29.21M | 29.22M | 29.22M |
| Weighted Avg Shares Out (Dil) | 39.62M | 29.94M | 29.21M | 29.22M | 29.22M |
Muscle Invasive Bladder Cancer Drug Pipeline Market Research 2024 Featuring Aura Biosciences, Janssen Research & Development, Asieris Pharmaceuticals, and RemeGen
This report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Muscle Invasive Bladder cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type,...
Aura Biosciences: 2 Positive Bel-Sar Data Releases Brings Shareholder Value
The positive end of phase 2 study data was achieved using bel-sar for the treatment of patients with intermediate lesions and small choroidal melanoma. The global uveal melanoma treatment market is expected to reach $2.4 billion by 2033. Positive data...
Aura Biosciences' Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade Disease
On Thursday, Aura Biosciences, Inc. AURA revealed early data from an ongoing Phase 1 trial of bel-sar (AU-011) in patients with non-muscle-invasive bladder cancer (NMIBC).
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial
Clinical Complete Responses Observed in 4 out of 5 Patients in Subset of Patients with Low Grade Disease; Evidence of Bladder Urothelial Field Effect in Non-Target Tumors
3 Small-Cap Stocks Ready to Deliver Significant Growth
Small-cap stocks faced a challenging environment for the last several years as inflation and high interest rates dampened lending opportunities. These companies—which are often in the early stages of development and lack stability—rely heavily on debt to fuel their growth.
Sept. 13-20 Undercovered Stock Picks: Aura Biosciences, APA Corporation, iTeos, CuriosityStream +
The 'Undercovered' Dozen series highlights 12 undercovered stocks to provide another source for investment ideas and to encourage community discussion. Qurate Retail's losses are mainly due to non-cash markdowns, making it a potential buy despite declining revenue and net income...
Aura Biosciences: Highly Derisked Late-Stage Eye Cancer Company
Aura Biosciences' lead asset, bel-sar, shows promising Phase 2 results for choroidal melanoma, with 80% tumor control and 90% vision preservation. Bel-sar's SPA designation by the FDA and its excellent safety profile position it favorably against current treatments like radiotherapy....
Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study
AURA stock up as lead candidate shows tumor control and visual acuity preservation abilities in eye cancer patients over 12 months of treatment.
Aura Biosciences Touts Promising Data From Eye Cancer Candidate
Thursday, Aura Biosciences, Inc. AURA revealed Phase 2 end-of-study results evaluating bel-sar (AU-011) for the first-line treatment of early-stage choroidal melanoma (CM), a vision and ocular cancer.
Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma
Bel-sar Demonstrated 80% Tumor Control Rate, 90% Visual Acuity Preservation, and a Highly Favorable Safety Profile Aura to Host a Virtual Ocular Oncology Investor Event Featuring Key Opinion Leaders Today at 8:00 am ET BOSTON, Sept. 12, 2024 (GLOBE NEWSWIRE)...
Source: https://incomestatements.info
Category: Stock Reports